274 related articles for article (PubMed ID: 29793415)
1. Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung.
Ozgencli I; Budak H; Ciftci M; Anar M
Anticancer Agents Med Chem; 2018; 18(11):1599-1605. PubMed ID: 29793415
[TBL] [Abstract][Full Text] [Related]
2. Anti-Cancer Activity of Lobaric Acid and Lobarstin Extracted from the Antarctic Lichen Stereocaulon alpnum.
Hong JM; Suh SS; Kim TK; Kim JE; Han SJ; Youn UJ; Yim JH; Kim IC
Molecules; 2018 Mar; 23(3):. PubMed ID: 29538328
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of the Inhibitory Effects of Anti-Cancer Drugs on Thioredoxin Reductase and Glutathione S-Transferase in Rat Liver.
Ozgencli I; Kilic D; Guller U; Ciftci M; Kufrevioglu OI; Budak H
Anticancer Agents Med Chem; 2018; 18(14):2053-2061. PubMed ID: 30198440
[TBL] [Abstract][Full Text] [Related]
4. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium(II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase.
Chen JC; Zhang Y; Jie XM; She J; Dongye GZ; Zhong Y; Deng YY; Wang J; Guo BY; Chen LM
J Inorg Biochem; 2019 Apr; 193():112-123. PubMed ID: 30711557
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
10. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
11. The anti-cancer efficacies of diffractaic, lobaric, and usnic acid:
Emsen B; Aslan A; Turkez H; Joughi A; Kaya A
J Cancer Res Ther; 2018; 14(5):941-951. PubMed ID: 30197329
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.
Qian J; Xu Z; Meng C; Liu J; Hsu PL; Li Y; Zhu W; Yang Y; Morris-Natschke SL; Lee KH; Zhang Y; Ling Y
Eur J Med Chem; 2020 Oct; 204():112610. PubMed ID: 32736231
[TBL] [Abstract][Full Text] [Related]
14. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II).
Sasada T; Nakamura H; Ueda S; Sato N; Kitaoka Y; Gon Y; Takabayashi A; Spyrou G; Holmgren A; Yodoi J
Free Radic Biol Med; 1999 Sep; 27(5-6):504-14. PubMed ID: 10490269
[TBL] [Abstract][Full Text] [Related]
15. 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage.
Zhou B; Huang J; Zuo Y; Li B; Guo Q; Cui B; Shao W; Du J; Bu X
Eur J Pharmacol; 2013 May; 707(1-3):130-9. PubMed ID: 23524096
[TBL] [Abstract][Full Text] [Related]
16. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
17. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
19. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
Yan J; Xu Y; Jin X; Zhang Q; Ouyang F; Han L; Zhan M; Li X; Liang B; Huang X
Eur J Med Chem; 2022 Jan; 227():113897. PubMed ID: 34649064
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
